表面活性物质替代治疗新生儿呼吸窘迫综合征的疗效评估

PDF(996 KB)

中国当代儿科杂志 ›› 2009, Vol. 11 ›› Issue (03) : 188-190.

新生儿疾病专栏

表面活性物质替代治疗新生儿呼吸窘迫综合征的疗效评估

Sedigheh GHAEMI, Maryam MOHAMADYMASODI, Roya KELISHADI

作者信息 +

Evaluation of the effects of surfactant replacement therapyin neonatal respiratory distress syndrome

Sedigheh GHAEMI, Maryam MOHAMADYMASODI, Roya KELISHADI

Author information +

文章历史 +

摘要

目的：呼吸窘迫综合征 (RDS) 是早产儿发病和死亡的重要原因。RDS主要由肺表面活性物质缺乏所致。该研究调查了表面活性物质治疗在减少早产儿死亡率中的作用，并评估了表面活性物质疗效与一些RDS相关危险因素的关系。方法：通过简单抽样抽取符合入选要求的89例RDS早产儿，他们均来自于 Shaheed Beheshti医院新生儿重症监护室。生后48 h内给予表面活性物质治疗(100 mg/kg)。结果：89例得到表面活性物质治疗的RDS早产儿中，34 例(38.2%) 幸存， 55例死亡。其中胎龄大于32周，表面活性物质治疗开始于生后24 h 内，1，5分钟Apgar 评分大于7/10分，或出生体重大于1 500 g者治疗效果较好，存活率分别为 47.5%, 43.3%, 48.1%，52.5%。表面活性物质治疗后母亲孕前经过激素治疗的RDS早产儿的存活率（41.7%）显著高于那些母亲孕前未经激素治疗者（34.2%）（P<0.05）。结论：表面活性物质替代治疗新生儿RDS应尽可能早地进行，能减少38.2%的死亡率。新生儿胎龄、出生体重、Apgar 评分、表面活性物质治疗开始时间及母亲孕期是否经激素治疗等均可影响表面活性物质替代治疗的疗效。［中国当代儿科杂志，2009，11（3）：188-190］

Abstract

OBJECTIVE: Respiratory distress syndrome (RDS) is a major cause of morbidity and mortality in preterm neonates. Pulmonary surfactant deficiency is the primary cause of RDS. The purpose of this study was to determine the effect of surfactant therapy in reduction of the mortality rate in premature neonates with RDS and to assess the relationship between the efficacy of surfactant therapy and some risk factors associated with RDS. METHODS: This study comprised 89 premature neonates with signs of RDS. The neonates were selected by simple sampling from those admitted to the Neonatal Intensive Care Unit (NICU) of Shaheed Beheshti Hospital. The eligible neonates received surfactant replacement-therapy (100 mg/kg) during 48 hours after birth RESULTS: Overall, 34 (38.2%) out of 89 neonates who received surfactant survived. The higher efficacy of surfactant replacement therapy was observed in neonates with gestational age of more than 32 weeks (47.5%), in those who received the first dose of surfactant during the first 24 hours of life (43.3%), in those with an Apgar score of more than 7/10 at 1 and 5 min (48.1%), and in those with a birth weight of more than 1 500 g (52.5%). The neonates whose mother received steroid therapy before labor had higher reduction in mortality after surfactant therapy (41.7% with steroid vs 34.2% without steroid; P<0.05). CONCLUSIONS: Surfactant replacement therapy in neonatal RDS should be started as soon as possible after birth. It could reduce the mortality rate from RDS by 38.2%. The efficacy of surfactant therapy for neonatal RDS may be associated with gestational age, Apgar score, birth weight, starting time of surfactant therapy and maternal steroid therapy. ［Chin J Contemp Pediatr, 2009, 11 (3):188-190］

导出引用

Sedigheh GHAEMI, Maryam MOHAMADYMASODI, Roya KELISHADI. 表面活性物质替代治疗新生儿呼吸窘迫综合征的疗效评估[J]. 中国当代儿科杂志. 2009, 11(03): 188-190

Sedigheh GHAEMI, Maryam MOHAMADYMASODI, Roya KELISHADI. Evaluation of the effects of surfactant replacement therapyin neonatal respiratory distress syndrome[J]. Chinese Journal of Contemporary Pediatrics. 2009, 11(03): 188-190

中图分类号： R766.18

参考文献

［1］Dudell GG, Stoll BJ. Respiratory distress syndrome (hyaline membrane disease)［M］. //Kliegman RM, Behrman RE, Jenson HB, Stanton BF. Nelson Text Book of Pediatrics. 18th ed. Phildelphia:Saunders Com, 2007, 731-740.
［2］Mantant S, Arulkumaran S. Neonatal respiratory distress syndrome［J］. Lancet, 2006, 367(9526):1878-1379.
［3］Suresh GK, Soll RF. Current surfactant use in premature infant［J］. Clin Perinatal, 2001, 28 (3): 671-694.
［4］Gonda TA, Hutchins GM. Surfactant treatment may accelerate epithelial cell regeneration in hyaline membrane disease of the newborn［J］. Am J Perinatol, 1998, 15(9):539-544.
［5］Ricardo J, Rodrigue Z. Respiratory distress syndrome, Fanaroff and Martin′s Neonatal Perinatal Medicine, Disease of the Fetus and infant［M］. Vol 2, 8th ed. St Louis:Mosby Com, 2006, 1097-1107.
［6］Bhakta K. Respiratory distress syndrome［M］.// Clpherty JP, Eichenwald EC, Stark AR. Manual of Neonatal Care. 6th ed. Baltmore:William & Wilkins Com, 2008, 323-330.
［7］Gautham K, Suresh M, Roger F. Exogenous surfactants［M］.//Goldsmith J, Karotkin E. Assisted ventilation of the neonate. 4th ed. Phildelphia: Saunders Com, 2003, 335-336.
［8］Kresch MJ, Lin WH, Thrall RS. Surfactant replacement therapy［J］. Thorax, 1996, 51(11):1137-1154.
［9］Gregory TJ, Steinberg KP, Spragg R, Gadek JE, Hyers TM, Longmore WJ, et al. Bovine surfactant therapy for patients with acute respiratory distress syndrome［J］. Am J Respiratory Critical Care Med, 1997, 155(4):1309-1315.
［10］Zola EM, Gunkel JH, Chan RK, Lim MO, Knox I, Feldman BH, et al. Comparison of three dosing procedures for administration of bovine surfactant to neonates with respiratory distress syndrome［J］. J Pediatr, 1993, 122(3):453-459.
［11］Jobe AH, Ikegami M. Biology of surfactant［J］. Clinic Perinatal, 2001, 28 (3):655-667.
［12］American Academy of Pediatrics, Committee on Fetus and Newborns. Surfactant replacement therapy for respiratory distress syndrome［J］. Pediatrics, 1999, 103(3):684-685.
［13］Crowther CA, Haslam RR, Hiller JE, Doyle LW, Robinson JS; Australasian Collaborative Trial of Repeat Doses of Steroids (ACTORDS) Study Group. Neonatal respiratory distress syndrome after repeat exposure to antenatal corticosteroids: a randomised controlled trial［J］. Lancet, 2006, 367(9526):1913-1919.
［14］Chen CM, Fang CL, Chang CH. Surfactant and corticosteroid effects on lung function in a rat model of acute lung injury［J］. Crit Care Med, 2001, 29(11):2169-2175.